Are there issues or risks to consider given patient's IgA Lambda form of the disease?
I also agree with the decision for maintenance therapy after transplant, either with Revlimid or on a clinical trial, if available. The two large phase III studies (CALGB 100104 and IFM 2005-02) currently investigating maintenance therapy post transplant have both demonstrated a near doubling of progression free survival with Revlimid maintenance therapy . Importantly, a recent update of the CALGB study also demonstrated a statistically significant improvement in overall survival. For patients with high-risk disease (and/or residual disease after HDM-ASCT), I discuss the risks and benefits of maintenance therapy and recommend therapy.
H. Lee Moffitt Cancer Center & Research Institute
Any advice provided in these postings is based on a very limited amount of information. There is no substitute for the care of your oncologist/hematologist. Therefore, all suggestions should be discussed with your treating physician. None of the comments presented here are meant to replace the evaluation of a patient by a knowledgeable physician.
Dr. Ken Shain
- Name: Ken Shain, M.D., Ph.D.
Beacon Medical Advisor